<?xml version="1.0" encoding="UTF-8"?><ns2:edgarSubmission xmlns:com="http://www.sec.gov/edgar/common" xmlns:ns2="http://www.sec.gov/edgar/ownership">
    <ns2:headerData>
        <ns2:submissionType>144</ns2:submissionType>
        <ns2:filerInfo>
            <ns2:filer>
                <ns2:filerCredentials>
                    <ns2:cik>0001359574</ns2:cik>
                    <ns2:ccc>XXXXXXXX</ns2:ccc>
                </ns2:filerCredentials>
            </ns2:filer>
            <ns2:liveTestFlag>LIVE</ns2:liveTestFlag>



        </ns2:filerInfo>
    </ns2:headerData>
    <ns2:formData>
        <ns2:issuerInfo>
            <ns2:issuerCik>0001556263</ns2:issuerCik>
            <ns2:issuerName>SYROS PHARMACEUTICALS, INC.</ns2:issuerName>
            <ns2:secFileNumber>001-37813</ns2:secFileNumber>
            <ns2:issuerAddress>
                <com:street1>35 Cambridge Park Drive</com:street1>
                <com:street2>4th Floor</com:street2>
                <com:city>Cambridge</com:city>
                <com:stateOrCountry>MA</com:stateOrCountry>
                <com:zipCode>02140</com:zipCode>
            </ns2:issuerAddress>
            <ns2:issuerContactPhone>1-617-744-1340</ns2:issuerContactPhone>
            <ns2:nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Nancy Cole</ns2:nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
            <ns2:relationshipsToIssuer>
                <ns2:relationshipToIssuer>Director</ns2:relationshipToIssuer>
            </ns2:relationshipsToIssuer>
        </ns2:issuerInfo>
        <ns2:securitiesInformation>
            <ns2:securitiesClassTitle>SYROS PHARMACEUTICALS, INC.</ns2:securitiesClassTitle>
            <ns2:brokerOrMarketmakerDetails>
                <ns2:name>Goldman Sachs &amp; Co. LLC</ns2:name>
                <ns2:address>
                    <com:street1>200 West Street</com:street1>
                    <com:city>New York</com:city>
                    <com:stateOrCountry>NY</com:stateOrCountry>
                    <com:zipCode>10282</com:zipCode>
                </ns2:address>
            </ns2:brokerOrMarketmakerDetails>
            <ns2:noOfUnitsSold>37070</ns2:noOfUnitsSold>
            <ns2:aggregateMarketValue>10016.31</ns2:aggregateMarketValue>
            <ns2:noOfUnitsOutstanding>26832457</ns2:noOfUnitsOutstanding>
            <ns2:approxSaleDate>12/02/2024</ns2:approxSaleDate>
            <ns2:securitiesExchangeName>NASDAQ</ns2:securitiesExchangeName>
        </ns2:securitiesInformation>
        <ns2:securitiesToBeSold>
            <ns2:securitiesClassTitle>SYROS PHARMACEUTICALS, INC.</ns2:securitiesClassTitle>
            <ns2:acquiredDate>08/24/2016</ns2:acquiredDate>
            <ns2:natureOfAcquisitionTransaction>Acquired as compensation -- Restricted Stock Units</ns2:natureOfAcquisitionTransaction>
            <ns2:nameOfPersonfromWhomAcquired>The Issuer</ns2:nameOfPersonfromWhomAcquired>
            <ns2:isGiftTransaction>N</ns2:isGiftTransaction>
            <ns2:amountOfSecuritiesAcquired>30404</ns2:amountOfSecuritiesAcquired>
            <ns2:paymentDate>08/24/2016</ns2:paymentDate>
            <ns2:natureOfPayment>Compensation</ns2:natureOfPayment>
        </ns2:securitiesToBeSold>
        <ns2:securitiesToBeSold>
            <ns2:securitiesClassTitle>SYROS PHARMACEUTICALS, INC.</ns2:securitiesClassTitle>
            <ns2:acquiredDate>10/17/2016</ns2:acquiredDate>
            <ns2:natureOfAcquisitionTransaction>Acquired as compensation -- Restricted Stock Units</ns2:natureOfAcquisitionTransaction>
            <ns2:nameOfPersonfromWhomAcquired>The Issuer</ns2:nameOfPersonfromWhomAcquired>
            <ns2:isGiftTransaction>N</ns2:isGiftTransaction>
            <ns2:amountOfSecuritiesAcquired>6666</ns2:amountOfSecuritiesAcquired>
            <ns2:paymentDate>10/17/2016</ns2:paymentDate>
            <ns2:natureOfPayment>Compensation</ns2:natureOfPayment>
        </ns2:securitiesToBeSold>
        <ns2:nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</ns2:nothingToReportFlagOnSecuritiesSoldInPast3Months>
        <ns2:noticeSignature>
            <ns2:noticeDate>12/02/2024</ns2:noticeDate>
            <ns2:planAdoptionDates/>
            <ns2:signature>Goldman Sachs &amp; Co. LLC on behalf of Nancy Cole</ns2:signature>
        </ns2:noticeSignature>
    </ns2:formData>
</ns2:edgarSubmission>
[{"type": "144", "sequence": "1", "filename": "primary_doc.xml", "secsgml_size_bytes": 4354}]
144
0001359574
XXXXXXXX
LIVE
0001556263
SYROS PHARMACEUTICALS, INC.
001-37813
35 Cambridge Park Drive
4th Floor
Cambridge
MA
02140
1-617-744-1340
Nancy Cole
Director
SYROS PHARMACEUTICALS, INC.
Goldman Sachs & Co. LLC
200 West Street
New York
NY
10282
37070
10016.31
26832457
12/02/2024
NASDAQ
SYROS PHARMACEUTICALS, INC.
08/24/2016
Acquired as compensation -- Restricted Stock Units
The Issuer
N
30404
08/24/2016
Compensation
SYROS PHARMACEUTICALS, INC.
10/17/2016
Acquired as compensation -- Restricted Stock Units
The Issuer
N
6666
10/17/2016
Compensation
Y
12/02/2024
Goldman Sachs & Co. LLC on behalf of Nancy Cole